AMPK Regulation of M1 Macrophage Polarization in Obesity-Related Asthma

Study Background and Research Question

Obesity-related asthma is a distinct clinical phenotype characterized by nonallergic, steroid-resistant airway inflammation and poor response to standard therapies. Unlike classic eosinophilic asthma, patients with obesity-related asthma demonstrate persistent symptoms and metabolic dysregulation, reflecting complex interactions between immune and metabolic pathways. M1 macrophages, as pro-inflammatory effectors, contribute to insulin resistance and chronic inflammation in obese individuals. Adenosine monophosphate-activated protein kinase (AMPK) is a master regulator of cellular energy homeostasis and metabolic balance and has been implicated in modulating inflammatory responses. However, the precise role of AMPK in macrophage polarization and airway inflammation in obesity-related asthma remains insufficiently defined. The reference study (Lei et al., 2025) addresses whether AMPK influences M1 macrophage polarization through the JAK2/STAT3 signaling pathway and examines the downstream effects on airway inflammation in obesity-related asthma models.

Key Innovation from the Reference Study

The central innovation of the study lies in elucidating the mechanistic link between AMPK activity and M1 macrophage polarization via the JAK2/STAT3 signaling axis. By demonstrating that AMPK activation can attenuate M1 polarization and suppress inflammatory cytokine production in both in vivo and in vitro models, the authors provide evidence for a regulatory pathway that connects metabolic sensing with immunoinflammatory outcomes. This positions AMPK not only as a metabolic checkpoint but also as a potential immunomodulatory target in the context of obesity-related asthma, where conventional anti-inflammatory strategies often fail.

Methods and Experimental Design Insights

The research employed a combination of in vivo and in vitro approaches. Mouse models of obesity-related asthma were established, and lung tissues were analyzed using hematoxylin-eosin (HE), periodic acid-Schiff (PAS), and Masson staining to assess airway and tissue pathology. Immunohistochemistry and immunofluorescence techniques were utilized to quantify macrophage polarization states within lung tissues. The study further leveraged RAW264.7 macrophage cell lines treated with lipopolysaccharide (LPS) to mimic inflammatory conditions. Quantitative real-time PCR (qRT-PCR), Western blotting, and ELISA assays provided quantitative measures of gene and protein expression for inflammatory markers, AMPK, and components of the JAK2/STAT3 pathway. Critically, specific pharmacological modulators were employed to manipulate AMPK activity and dissect pathway dependencies.

Core Findings and Why They Matter

Key findings from the study include:

• Increased M1 macrophage polarization was observed in the lungs of obesity-related asthmatic mice, accompanied by a marked decrease in AMPK expression (Lei et al., 2025).
• Exogenous activation of AMPK in LPS-stimulated RAW264.7 cells led to significant reduction in M1 polarization and pro-inflammatory cytokine secretion, indicating a negative regulatory role for AMPK in macrophage-driven inflammation.
• JAK2/STAT3 signaling was identified as a mechanistic mediator of AMPK’s effects. Specifically, AMPK activation suppressed JAK2 and STAT3 phosphorylation, thereby modulating downstream inflammatory responses.
• In vivo, AMPK activation alleviated airway inflammation in obese asthmatic mice, as evidenced by improved histopathology and reduced expression of inflammatory mediators.

These results are significant because they highlight a pathway—AMPK-JAK2/STAT3—that integrates metabolic and immunological signals, offering a rational target for intervention in obesity-related asthma, a condition that is often refractory to standard corticosteroid therapy. The data suggest that restoring AMPK activity can shift macrophage polarization away from the pro-inflammatory M1 phenotype, potentially ameliorating airway inflammation and improving clinical outcomes.

Comparison with Existing Internal Articles

Several internal articles have previously explored the role of AMPK and related signaling pathways in cellular metabolism, autophagy regulation, and differentiation processes. For example, one thought-leadership article emphasizes Dorsomorphin (Compound C) as a dual inhibitor of AMPK and BMP/Smad signaling, facilitating the study of metabolic and differentiation pathways in various disease models. Another guide (Applied Protocols in AMPK and BMP Research) provides practical insights for dissecting AMPK-regulated metabolism and macrophage function, aligning with the reference study’s focus on macrophage polarization. These resources corroborate the reference study’s findings by underscoring the translational potential of AMPK pathway inhibitors and activators in immunometabolic research. However, the current paper advances the field by demonstrating the direct interplay between AMPK activity and the JAK2/STAT3 axis in the specific context of obesity-related asthma, a connection only partially addressed in prior literature.

Limitations and Transferability

While the study offers robust evidence for the AMPK-JAK2/STAT3 pathway in regulating macrophage polarization and airway inflammation, several limitations merit consideration. The mouse models and RAW264.7 cell lines, though informative, may not fully recapitulate the complex pathophysiology of human obesity-related asthma. The pharmacological agents used to modulate AMPK activity may have off-target effects, and the specificity of the observed outcomes to the AMPK-JAK2/STAT3 axis warrants further validation using genetic approaches. Additionally, the translational applicability of these findings to clinical populations remains to be established, particularly regarding long-term effects and safety of AMPK-targeted interventions.

Protocol Parameters

• In vivo AMPK modulation: Administer AMPK activators or inhibitors daily during model induction and assessment phases to study airway inflammation and macrophage polarization.
• RAW264.7 cell stimulation: Treat cells with LPS (e.g., 100 ng/mL) to induce M1 polarization; apply AMPK modulators 30 minutes prior to LPS challenge for pathway dissection.
• Inflammatory marker assessment: Collect supernatants and cell lysates 24 hours post-stimulation for ELISA, qRT-PCR, and Western blot analysis of cytokines and pathway proteins.
• Histological and immunostaining: Fix and stain lung tissues using HE, PAS, and Masson protocols to evaluate airway remodeling and inflammation.

Research Support Resources

Researchers aiming to dissect AMPK pathway regulation, autophagy, or the inhibition of AMPK activity in hepatocytes and immune settings may consider utilizing Dorsomorphin (Compound C) (SKU B3252). This selective, reversible ATP-competitive AMPK inhibitor has been widely applied in studies of metabolic modulation, autophagy regulation, and the inhibition of pathways such as BMP4-induced SMAD phosphorylation, as detailed in both the product information and internal literature. APExBIO provides Dorsomorphin as a solid, DMSO-soluble reagent suitable for both in vitro and in vivo experimentation. Integration of this tool can support the validation and extension of AMPK-related mechanisms in macrophage polarization and airway inflammation models.